Summary A prospective study was performed to evaluate the feasibility of full dose chemotherapy given on schedule in elderly patients with unfavourable non-Hodgkin's lymphoma, stage E, III and IV. Using a combination regimen of six courses of cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) given every 4 weeks, no serious toxicity was encountered in a group of 30 consecutive patients with a mean age of 70.4 years. A 60% complete response rate was observed and a total response rate of 90%. The disease-free survival of complete responders was 50% at 1 year. The overall survival was also 50% at 1 year. In 148 courses of CNOP only two serious infectious episodes were noted, i.e. one herpes zoster infection and one case of bronchopneumonia. Asymptomatic transient thrombocytopenia and granulocytopenia were commonly observed. Nadirs of white blood cells were WHO grade 1, 2, 3 and 4 in six, five, twelve and two patients respectively and nadirs of thrombocytopenia were WHO grade 0 and 1 (22 patients) or 2 (three patients). (Dixon et al., 1986) . The decision to reduce the dose of cytostatic drugs in this group of patients is generally based on their age only, even if concomitant disease is not present. However, not all studies show that age is an independent prognostic factor and among other causes reduced drug doses may contribute to the poorer survival of elderly patients in these studies (Jagannath et al., 1985; O'Connell et al., 1986; Dixon et al., 1986) .
The present study was initiated to test the feasibility of such a strategy. Doxorubicin is a major drug in most regimens for non-Hodgkin's lymphoma, and in the CHOP regimen it may contribute to cardiac morbidity, which was the second cause of death in a study on treatment of NHL in the elderly (Armitage & Potter, 1984) . Mitoxantrone is a DNA intercalating drug with less cardiotoxicity than doxorubicin, while being equally effective in malignant lymphoma (Dansey & Bezwoda, 1987 exclusion criterion in all ongoing national and EORTC trials for adults with malignant lymphoma. Two patients below 60 years were included because concomitant heart disease made them ineligible for other treatment protocols. All patients were staged by routine blood examination, chest roentgenography, computerised tomography of abdomen and computerised tomography of the thorax in case of abnormal chest roentgenography, bone marrow puncture and/or biopsy.
The median follow-up of all patients was 16 months (range 3-38 months). The median follow-up of complete responders was 24 months (range 5-38 months).
Methods
Malignant non-Hodgkin's lymphoma was diagnosed according to the working Formulation and the Ann Arbor classification (National Cancer Institute, 1982 Results the total number of responders was 27 (90%). The overall survival and the disease-free survival of patients in complete remissions are given in Figure 1 . At present there are nine patients surviving more than 2 years, with a median followup of 23 months.
Toxicity
Frequent haematological surveillance following the first course of CNOP showed that asymptomatic thrombocytopenia and leukocytopenia, in particular granulocytopenia, were commonly observed at days 10-14 following treatment (Table II) in these patients. Toxicity other than granulocytopenia was minor. Table II gives the maximal WHO toxicity score encountered in each patient during successive courses of CNOP. Unacceptable toxicity did not occur. In six patients with a history of cardiac illness who could be evaluated after five or six courses of CNOP a left ventricular ejection was performed before and after completing therapy. These patients all had a pretreatment left ventricular ejection fraction of 40-70%. No significant reduction of the ventricular output following CNOP therapy was noted in any patient.
Discussion
Advanced non-Hodgkin's lymphoma of intermediate or high grade malignancy not restricted to a single site is usually treated with combination chemotherapy. Complete response rates of stage II-IV unfavourable NHL ranging from 40 to 80% can be achieved using anthracycline-containing regimens like ProMaceMOPP (Fisher et al., 1983) , M-BACOD (Skarin et al., 1983) , COP-BLAM (Laurence et al., 1982) , MACOP-B (Klimo & Connors, 1987) and CHOP (Armitage et al., 1986) . In these studies a high complete response rate is associated with improved survival. The toxicity of these regimens is, however, considerable and a significant number of elderly patients may not complete the required number of chemotherapy courses (Connors, 1988) , due to a poor performance status and/or considerable therapy-related morbidity (Anderson et al., 1982; Goh & Williams, 1983; Armitage & Potter, 1984; Mead et al., 1984; O'Connell et al., 1986) . Several studies have found a poorer prognosis of unfavourable NHL in elderly patients when compared to their younger counterparts (Jagannath et al., 1985; Solal-Celigny et al., 1987; Fisher et al., 1987; Dixon et al., 1986) . Among other causes, such a difference of response may be related to less intensive treatment due to initial dose reductions of the drugs administered to elderly patients (Boyd et al., 1988) . Therefore it may be expected that full dose chemotherapy given on schedule will lead to better complete response rates in elderly patients, provided that the toxicity of such an approach is acceptable (O'Connell et al., 1986; Dixon et al., 1986) . In CHOP-like regimens the initial dose of doxorubicin was frequently reduced because of expected toxicity (Dixon et al., 1986) . If doxorubicin is replaced by mitoxantrone, a less toxic anthraquinone drug, full dose chemotherapy may be better tolerated by elderly patients with extensive nonHodgkin's lymphoma.
There is no direct comparison of the efficacy of doxorubicin alone and mitoxantrone alone in elderly patients with untreated lymphoma. In a study by Brusamolino, comparing CNOP and CHOP in lymphoma patients not selected for age, mitoxantrone at a dose of 12 mg m 2 was given (Dansey & Bezwoda, 1987; Brusamolino et al., 1988) . They observed a lower leucocyte nadir in the CNOP treated patients. In another study M-BACOD was compared with the identical regimen except for the exchange of mitoxantrone at 10 mg m2 for doxorubicin, where no therapeutic difference was found in a population with NHL not selected for age (Case et al., 1988) . In a similar fashion mitoxantrone at a dose of 10 mg m2 was selected for the present study.
A response rate of 90% with 60% complete responses was obtained without significant adverse side-effects. In those patients who completed five or more courses of CNOP the complete response rate was 80%. These results are comparable with or even better than the complete response rates published by Dixon et al. (1986) for the same age group treated with CHOP. The disease-free and overall survival is somewhat less than in younger patients receiving CNOP (Brusamolino et al., 1988 ) (50 vs 70%). However, the relapse-free survival at 2 years is comparable with that of elderly patients in previously published studies using CHOP (Armitage & Potter, 1984; Dixon et al., 1986) . Thus, CNOP appears to be a good alternative to doxorubicin-containing regimens. This was further determined by two studies comparing CNOP with CHOP in a group of patients not selected for age, in which no therapeutic difference was found (Dansey & Bezwoda, 1987; Brusamolino et al., 1988) . Based on these results we have now started a prospective randomised clinical study in patients over 60 years of age with unfavourable NHL, to compare full dose CNOP versus CHOP with respect to toxicity, response rate and survival.
